No abstract

Cognition is a group of mental processes that includes the capacity to perceive, think, learn and to study, and the capacity of the brain to analyze information and program adaptive behaviour. Although there has been an appreciable evolution in the therapy of psychoses in the last twenty-five years, cognitive disturbances still persist in spite of antipsychotic treatment. The cognitive decay disrupts the ability of clinically diagnosed patients with psychoses, mainly schizophrenia, to learn and to memorize skills that are useful for their family and social relationships. Moreover, cognitive deficiency is often considered to be crucial for further rehabilitation. In atypical antipsychotics there are big differences in the effects on cognitive functions. Some clinical studies demonstrate the benefits of a third generation of antipsychotics on cognitive functions in patients treated for mental illnesses. In the present study we have reviewed many articles investigating the influence of aripiprazole on cognition in human and animal subjects. Aripiprazole is a third generation antipsychotic drug that possesses a unique pharmacodynamic profile, which in conjunction with recently published scientific data on the drugs' influence on antidepressant, anxiolytic and cognitive functions, suggests a highly positive future potential for restorative cognitive treatment and ongoing healthy function. The data included in the review will contribute to determining the potential benefits of aripiprazole on memory and training processes.

New brain technologies including neuroimaging studies are powerful means for providing new insights into clinical and cognitive neuroscience. Bipolar disorder is a severe chronic phasic mental disease characterized by various cognitive dysfunctions. Working memory is one prominent domain of cognitive impairment in bipolar disorder. Disruptions in working memory are observed even in euthymic bipolar patients which makes it a potential endophenotypic marker for the disorder. Finding such markers may help in providing firm neurobiological basis for psychiatric nosologies and symptomatic presentations. This review aims to summarize some of the important aspects of findings from functional magnetic resonance imaging studies on the activation of brain structures in relation to working memory paradigms.

Aim:The aim of this study was to compare the activity of the autonomic nervous system (ANS) using heart rate variability (HRV) in 'healthy' young smokers and non-smokers before, during and after exogenous hypoxic provocation. Methods: Twenty-one healthy non-smoking males aged 28.0 ± 7.4 years (mean ± SD) and 14 'healthy' smoking males aged 28.1 ± 4.3 years with 9.2 ± 5.6 pack-years were subjected to one-hour hypoxic exposure (F i O 2 = 12.3 ± 1.5%) via a hypoxicator. HRV data was derived via Kubios HRV, Finland software by analysing the pre-hypoxic, hypoxic and post-hypoxic periods. Results: Standard deviation of the intervals between normal beats (SDNN) was higher in the non-smokers in the prehypoxic period (62.0 ± 32.1 vs 40.3 ± 16.2 ms, p = 0.013) but not in the hypoxic period (75.7 ± 34.8 vs 57.9 ± 18.3 ms, p = 0.167). When comparing intra-group HRV changes, shifting from hypoxic to normoxic conditions, there was an increase in the mean square root of successive R-R interval differences (RMSSD) (65.9 ± 40.2 vs 75.1 ± 45.9 ms, p = 0.011), but these changes were observed in only the group of non-smokers. Conclusions:Smoking probably impairs autonomic regulation in healthy young males and may lead to decreased HRV, even before subjective clinical signs and symptoms appear. MethodsTwenty-one healthy male non-smokers and 16 'healthy' male smokers with 9.2 ± 5.6 (mean ± SD) pack-years were included in the study. All the subjects had regular physical activity and no

AbstractThe introduction of the second generation triptans in clinical and experimental practice was a major progress in the pharmacotherapy of migraine. Frovatriptan is a second generation triptan with strong 5-HT1B/1D serotonergic agonism and low 5-HT1A/7 receptor affinity, while almotriptan possesses not only the typical 5-HT1B/1D receptor agonist activity, but shows an affinity to the 5-HT1F receptor. The aim of our study was to assess the impact of frovatriptan and almotriptan on hemodynamics in male and female rats. We used a non-invasive “tail-cuff” method to measure the arterial blood pressure. Female and male Wistar rats were treated separately with high and low dosages of frovatriptan and almotriptan. Male and female rats showed reduction in all hemodynamic parameters, but only male rats showed an increase in the heart rate. In general, we could say that both almotriptan and frovatriptan potentiate cardiovascular safety.